NCT01570868View on ClinicalTrials.gov

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

PHASE2TerminatedINTERVENTIONAL

Enrollment

51

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions

Leukemia

Interventions

DRUG

Ponatinib

Starting dose: 45 mg by mouth once daily.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Ariad Pharmaceuticals

All Listed Sponsors

collaborator

Ariad Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01570868 - Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) | Biotech Hunter | Biotech Hunter